Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.

[1]  R. Vij,et al.  Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. , 2023, The New England journal of medicine.

[2]  M. Liedtke,et al.  Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results , 2023, Nature Medicine.

[3]  S. Montoto,et al.  Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. , 2022, The Lancet Haematology.

[4]  F. Zhan,et al.  Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma , 2022, JAMA network open.

[5]  H. Goldschmidt,et al.  LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma , 2022, Leukemia.

[6]  E. Giné,et al.  Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation , 2022, Frontiers in Oncology.

[7]  E. Giné,et al.  Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy , 2021, Journal for ImmunoTherapy of Cancer.

[8]  F. Prósper,et al.  Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) , 2021, Blood.

[9]  Jianfeng Zhou,et al.  Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials , 2021, Frontiers in Immunology.

[10]  Chiung-Yu Huang,et al.  Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy , 2021, Blood advances.

[11]  S. Jagannath,et al.  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.

[12]  Alexandra Martínez-Roca,et al.  Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak , 2021, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[13]  M. Beksac,et al.  Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations , 2021, British journal of haematology.

[14]  H. Goldschmidt,et al.  Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. , 2021, The Lancet. Oncology.

[15]  H. Goldschmidt,et al.  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.

[16]  Z. Berneman,et al.  Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma , 2020, Journal of Hematology & Oncology.

[17]  E. Giné,et al.  CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  S. Rives,et al.  Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial , 2020, Frontiers in Immunology.

[19]  G. Gutiérrez-García,et al.  A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe , 2020, Bone Marrow Transplantation.

[20]  M. Juan,et al.  Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma , 2020, Haematologica.

[21]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[23]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.